Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with carboplatin + paclitaxel with or without bevacizumab versus carboplatin + paclitaxel + bevacizumab in first-line stage IV non-squamous NSCLC
NL-OMON47780Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + carboplatin + paclitaxel, Atezolizumab + carboplatin + paclitaxel + bevacizumab and Carboplatin + paclitaxel + bevacizumab (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Mar 2016; status: active, not recruiting.
02
Drugs
atezolizumabcarboplatinpaclitaxelbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47780.